Moguisteine is a non-narcotic, peripherally acting antitussive.

[1] In a small double-blind, randomized controlled trial, 200 mg of moguisteine suspension taken 3 times daily significantly reduced the frequency of coughing in patients with COPD, compared to placebo.

[2] It has also been studied in small trials in comparison to codeine[3] and dextromethorphan,[4] and has similar efficacy to both.

[5] It was discovered by searching for expectorants of the thiazolidine class, when compounds with a cough suppressant effect were accidentally found and moguisteine was selected as the most effective and safest representative of the class.

[6] Its mechanism of action may be the activation of ATP-sensitive potassium channels.